Source comparison
CJC-1295 no DAC & Ipamorelin Synergistic GH Protocols: Comparison
Understanding how CJC-1295 no DAC and Ipamorelin compare to alternative GH stimulation strategies is essential for protocol design. The table below contrasts this synergistic protocol against single-peptide use, long-acting analogs, and direct GH administratio
This comparison does not assign a generated winner or score.
- Understanding how CJC-1295 no DAC and Ipamorelin compare to alternative GH stimulation strategies is essential for protocol design. The table below contrasts this synergistic protocol against single-peptide use, long-acting analogs, and direct GH administration.
- | Protocol | Mechanism | GH Pulse Pattern | Typical Dosing | Side Effect Profile | Cost per Month | Bottom Line ||—|—|—|—|—|—|| CJC-1295 no DAC + Ipamorelin | Dual GHRH + ghrelin receptor agonism | Pulsatile (3–5× baseline amplitude) | 100–200 mcg CJC + 200–300 mcg Ipa, 2–3×/day | Minimal. No cortisol or prolactin elevation | $180–$280 | Best balance of physiological mimicry, safety, and cost. Ideal for research requiring natural GH dynamics || Ipamorelin Alone | Ghrelin receptor agonism only | Pulsatile (2–3× baseline amplitude) | 200–300 mcg, 2–3×/day | Minimal | $120–$180 | Effective but lower pulse amplitude without GHRH synergy. Suitable for mild GH stimulation research || CJC-1295 with DAC | Long-acting GHRH analog | Sustained elevation (non-pulsatile) | 2 mg once weekly | Moderate. Sustained elevation may disrupt sleep, increase prolactin | $80–$120 | Not recommended for protocols requiring pulsatile GH. Pharmacokinetics incompatible with natural physiology || MK-677 (Ibutamoren
- The synergistic protocol offers the highest GH pulse amplitude while preserving natural pulsatility. A combination no other approach achieves. For research applications measuring metabolic outcomes, tissue repair signaling, or receptor sensitivity dynamics, this distinction is critical.